文献速递鼻科

难治性慢性鼻窦炎伴鼻息肉患者度普利尤单抗治疗1年影像学与临床结局比较:一项真实世界研究

Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study.
PubMed 文献 · Laryngoscope · 2023-12-21

该真实世界研究纳入53例接受度普利尤单抗治疗的难治性慢性鼻窦炎伴鼻息肉(CRSwNP)患者,基线及治疗12个月时行CT检查,其中30例完成52周CT随访。结果显示,12个月时Lund-Mackay评分、SNOT-22、VAS、鼻息肉评分(NPS)及Lund-Kennedy评分(LKS)均显著降低(p<0.05);52周时LM、SNOT-22、VAS及NPS较12个月进一步显著下降,但LKS无显著变化(p=0.420)。

要点

  • 12个月时患者报告结局(SNOT-22)改善幅度最大(56.26%),鼻息肉大小(NPS)改善49.83%。
  • 12至52周期间,鼻窦浑浊(LM评分)改善最明显(36.86%),LKS无显著变化(p=0.420)。
  • 作者认为,度普利尤单抗对难治性CRSwNP患者的影像学、内镜及临床疾病严重程度均有显著改善。

核心结论

  • 作者经验显示,接受度普利尤单抗治疗的难治性CRSwNP患者在影像学、内镜及临床疾病严重程度方面均获得显著改善。
  • 作者认为,在初始3个月内患者报告结局较早显示疗效,而影像学结局在更长期显示出持续且逐渐的疗效。

研究设计与样本

  • 非随机回顾性队列研究,证据等级为Level 4(根据牛津循证医学中心2011年证据等级指南)。
  • 连续纳入接受度普利尤单抗治疗的难治性CRSwNP患者,要求基线(T0)及首次给药后12个月(T1)行CT检查,部分患者52周(T2)行CT检查以评估长期结局。
  • 共纳入53例患者,其中30例完成T2随访。

主要发现

  • 从T0至T1,平均Lund-Mackay评分(LM)、患者报告结局(SNOT-22、VAS)及内镜评分(NPS、LKS)均显著降低(p<0.05)。
  • 在达到T2的30例患者中,与T1相比,平均LM、SNOT-22、VAS及NPS评分进一步显著下降,但LKS无显著变化(p=0.420)。
  • T1时改善幅度最大的是患者报告结局(SNOT-22:56.26%)和鼻息肉大小(NPS:49.83%)。
  • T1至T2期间,鼻窦浑浊(LM:36.86%)为改善最明显的结局。

关键数值与推荐

  • T0至T1:平均LM、SNOT-22、VAS、NPS及LKS评分均显著降低(p<0.05)。
  • T1至T2(n=30):平均LM、SNOT-22、VAS及NPS评分进一步显著下降;LKS无显著变化(p=0.420)。
  • T1时SNOT-22改善56.26%,NPS改善49.83%;T1至T2期间LM改善36.86%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide real-life evidence on long-term radiological changes in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) treated with dupilumab, and to assess possible differences between radiological and clinical results in terms of endoscopic findings and Patient-Reported-Outcomes (PROs). METHODS: Consecutive patients treated with dupilumab for recalcitrant CRSwNP were required to undergo CT scan at baseline (T0) and after 12 (T1) since first administration. A group of patients also performed CT scan at 52 weeks (T2) to assess long-term outcomes. At each timepoint, patients underwent nasal endoscopy, assessment of Nasal-Polyp-Score (NPS), Lund-Kennedy-Score (LKS), and had to fill in the 22-item Sinonasal-Outcome-Test (SNOT-22) and Visual-Analogue-Scales (VAS) for sinonasal symptoms. RESULTS: In fifty-three included patients, from T0 to T1 we detected a significant reduction in mean Lund-Mackay score (LM), PROs (SNOT-22, VAS) and endoscopic (NPS, LKS) scores (p < 0.05). In the subset of patients that reached T2 (n = 30), compared to T1, we observed a further significant decrease in mean LM, SNOT-22, VAS, and NPS scores, but not in LKS (p = 0.420). At T1, the highest improvement was observed in PROs (SNOT-22: 56.26%), and polyp size (NPS: 49.83%). Conversely, between T1 and T2, sinus opacification was shown to be the most improved outcome (LM: 36.86%). CONCLUSIONS: Our experience showed that poorly controlled CRSwNP patients treated with dupilumab experienced significant improvement in radiologic, endoscopic and clinical disease severity. While in the initial 3 months, PROs garnered attention for showing earlier effectiveness, radiological outcomes revealed sustained and gradual efficacy in a longer term. LEVEL OF EVIDENCE: Level 4. According to the Oxford Center for Evidence-Based Medicine 2011 level of evidence guidelines, this non-randomized retrospective cohort study is classified as level 4 evidence Laryngoscope, 134:2626-2633, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Giombi F, Pace GM, Nappi E, et al. Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study. Laryngoscope. 2023. PMID: 38126613. doi:10.1002/lary.31238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。